UK startup Cerebella launches self-guided programme for menopause-related brain fog

Why menopause brain fog lacks solutions

Menopause-related brain fog affects 40–80% of women during the menopause transition, yet it lacks a clinical definition or established treatment. A survey of 1,300 to 1,400 women in the UK found that brain fog is linked to reduced confidence, lower productivity, and intentions to leave work. Traditional cognitive tests, often developed using male-dominated populations, are not sensitive to the subtle changes women experience.

The absence of validated tools and awareness in healthcare means symptoms are frequently misdiagnosed as other conditions, such as early-onset dementia. This gap leaves women without effective support, affecting their careers and quality of life.

How the programme works

Cerebella Foundations is a self-guided programme developed by cognitive neuroscientists to help women manage cognitive health during menopause. The programme includes ten sessions over five weeks and is based on evidence-based strategies. A proof-of-concept study by Cerebella reported improvements in verbal memory, attention, and sleep.

The startup also offers a free, lighter version of the programme, focusing on education and cognitive activities without collecting sensitive health data. This version aims to make support more accessible while addressing data privacy concerns.

Path to clinical adoption and funding

Cerebella is currently raising a pre-seed funding round and developing commercial pilots with employers. The company’s long-term goal is to achieve clinical validation, enabling recommendations and reimbursement through healthcare systems. It is also working to address gaps in menopause research, including the underrepresentation of women from diverse ethnic and cultural backgrounds.

What this means

Lazyfounder analysis — our interpretation, not reported fact.

Cerebella’s launch of Cerebella Foundations underscores a significant opportunity in the digital health sector: addressing menopause-related cognitive symptoms, which have long been overlooked in both medical research and clinical care. For founders and operators, this signals a growing market where evidence-based, scalable solutions can fill critical gaps in women’s health. The startup’s focus on neuroscience-backed interventions and its pursuit of clinical validation could set a precedent for how healthtech companies approach reimbursement and employer adoption in underserved areas.

Key takeaways

• Menopause-related cognitive challenges represent a large, underserved market with no established clinical solutions, creating opportunities for healthtech startups.
• Cerebella’s model—combining research with self-guided programmes—offers a potential pathway for clinical validation and reimbursement in women’s health.
• Employers may increasingly seek solutions like Cerebella Foundations to mitigate productivity and retention challenges linked to menopause symptoms.

Related on Lazyfounder

• More health news